» Articles » PMID: 32168864

Applying the Host-Microbe Damage Response Framework to Pathogenesis: Current and Prospective Strategies to Reduce Damage

Overview
Journal J Fungi (Basel)
Date 2020 Mar 15
PMID 32168864
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Disease is a complex outcome that can occur as a result of pathogen-mediated damage, host-mediated damage or both. This has led to the revolutionary concept of the damage response framework (DRF) that defines microbial virulence as a function of host immunity. The DRF outlines six scenarios (classes) of host damage or beneficial outcomes, depending on the microbe and the strength of the immune response. is uniquely adapted to its human host and can exist as either a commensal, colonizing various anatomical sites without causing notable damage, or as a pathogen, with the ability to cause a diverse array of diseases, ranging from mucosal to invasive systemic infections that result in varying levels of microbe-mediated and/or host-mediated damage. We recently categorized six different forms of candidiasis (oropharyngeal, hematogenous, intra-abdominal, gastrointestinal, denture stomatitis, and vulvovaginitis) into independent DRF classes, supporting a contemporary view of unique mechanisms of pathogenesis for these infections. In this review, we summarize the evidence for the pathogenesis of these various forms of candidiasis in the context of the DRF with the further intent to provide insights into strategies to achieve a level of host response or outcome otherwise, that limits host damage.

Citing Articles

mGem: A quarter century with the Pirofski-Casadevall damage response framework-a dynamic construct for understanding microbial pathogenesis.

Nosanchuk J mBio. 2025; 16(3):e0294524.

PMID: 39932289 PMC: 11898690. DOI: 10.1128/mbio.02945-24.


Profiling inflammatory outcomes of colonization and food allergy induction in the murine glandular stomach.

Zeise K, Falkowski N, Stark K, Brown C, Huffnagle G mBio. 2024; 15(11):e0211324.

PMID: 39347572 PMC: 11559088. DOI: 10.1128/mbio.02113-24.


A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens.

Yan J, Nielsen T, Lu P, Talyansky Y, Slarve M, Reza H Sci Transl Med. 2023; 15(716):eadf9556.

PMID: 37792959 PMC: 10947341. DOI: 10.1126/scitranslmed.adf9556.


Divergent EGFR/MAPK-Mediated Immune Responses to Clinical Pathogens in Vulvovaginal Candidiasis.

Zhang J, Peng J, Li D, Mei H, Yu Y, Li X Front Immunol. 2022; 13:894069.

PMID: 35720274 PMC: 9204526. DOI: 10.3389/fimmu.2022.894069.


In vitro activities of and extracts combined with amphotericin B against in production of hydrolytic enzymes.

Tefiani I, Seddiki S, Yassine Mahdad M Curr Med Mycol. 2021; 6(3):27-32.

PMID: 33834140 PMC: 8018827. DOI: 10.18502/cmm.6.3.4499.


References
1.
Beck B, Park G, Lee Y, Im S, Jeong D, Kang J . Whole Genome Analysis of Strains Isolated From Kimchi and Determination of Probiotic Properties to Treat Mucosal Infections by and . Front Microbiol. 2019; 10:433. PMC: 6414439. DOI: 10.3389/fmicb.2019.00433. View

2.
Gabrielli E, Pericolini E, Ballet N, Roselletti E, Sabbatini S, Mosci P . Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasis. Benef Microbes. 2018; 9(2):219-230. DOI: 10.3920/BM2017.0099. View

3.
Yano J, Lilly E, Barousse M, Fidel Jr P . Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect Immun. 2010; 78(12):5126-37. PMC: 2981313. DOI: 10.1128/IAI.00388-10. View

4.
Willems H, Lowes D, Barker K, Palmer G, Peters B . Comparative Analysis of the Capacity of the Species To Elicit Vaginal Immunopathology. Infect Immun. 2018; 86(12). PMC: 6246903. DOI: 10.1128/IAI.00527-18. View

5.
Cross L, Williams D, Sweeney C, Jackson M, A O Lewis M, Bagg J . Evaluation of the recurrence of denture stomatitis and Candida colonization in a small group of patients who received itraconazole. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(3):351-8. DOI: 10.1016/j.tripleo.2003.10.006. View